1. Home
  2. UTSI vs INAB Comparison

UTSI vs INAB Comparison

Compare UTSI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UTStarcom Holdings Corp.

UTSI

UTStarcom Holdings Corp.

HOLD

Current Price

$2.43

Market Cap

23.7M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.77

Market Cap

22.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UTSI
INAB
Founded
1991
2016
Country
China
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
22.9M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
UTSI
INAB
Price
$2.43
$1.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$180.00
AVG Volume (30 Days)
2.1K
28.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.94
$0.12
52 Week High
$2.94
$4.20

Technical Indicators

Market Signals
Indicator
UTSI
INAB
Relative Strength Index (RSI) 49.51 47.91
Support Level $2.38 $1.52
Resistance Level $2.55 $1.81
Average True Range (ATR) 0.05 0.13
MACD -0.00 0.02
Stochastic Oscillator 55.88 70.73

Price Performance

Historical Comparison
UTSI
INAB

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: